Inhibition of smooth muscle myosin as a novel therapeutic target for hypertension

Journal of Pharmacology and Experimental Therapeutics

Volumn 339, Issue 1, 2011, Pages 307-312

  Zhao, Xin ^a   Ho, David ^a   Abarzúa, Patricio ^b   Dhar, Sunil K ^c   Wang, Xi ^d   Jia, Zhiheng ^d   Pannirselvam, Malar ^d   Morgans, David J ^d   Malik, Fady I ^d   Vatner, Stephen F ^a,b  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b CV Dynamics Inc   (United States)

^c NEW JERSEY INSTITUTE OF TECHNOLOGY   (United States)

^d Cytokinetics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; CK 2018448; CK 448; MYOSIN; N,N' ALKYLUREA DERIVATIVE; UNCLASSIFIED DRUG; UREA DERIVATIVE;

ANIMAL EXPERIMENT; AORTA PRESSURE; ARTICLE; ASCENDING AORTA; BLOOD FLOW; CONTROLLED STUDY; DOG; DOPPLER FLOWMETER; DRUG EFFICACY; DRUG TARGETING; FEMALE; HEART LEFT VENTRICLE PRESSURE; HEART OUTPUT; HYPERTENSION; ILIAC ARTERY; KIDNEY BLOOD FLOW; MEAN ARTERIAL PRESSURE; NONHUMAN; PERIPHERAL EDEMA; PRIORITY JOURNAL; RENAL ARTERY; RENOVASCULAR HYPERTENSION; SMOOTH MUSCLE; VASCULAR RESISTANCE; VASODILATATION;

AMLODIPINE; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIAC OUTPUT; DOGS; FEMALE; HEMODYNAMICS; HYPERTENSION; ILIAC ARTERY; INJECTIONS, INTRAVENOUS; MUSCLE, SMOOTH; MYOSINS; RATS; RATS, INBRED SHR; REGIONAL BLOOD FLOW; RENAL CIRCULATION; UREA; VASCULAR RESISTANCE;

EID: 80053142823     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.182402     Document Type: Article

References (29)

1. Babu GJ, Loukianov E, Loukianova T, Pyne GJ, Huke S, Osol G, Low RB, Paul RJ, and Periasamy M (2001) Loss of SM-B myosin affects muscle shortening velocity and maximal force development. Nat Cell Biol 3:1025-1029. (Pubitemid 34428749)
2. Clancy S, Jia Z, Pannirselvam M, Qian X, Morgan B, Malik F, and Hartman J (2010) The small-molecule smooth muscle myosin inhibitor, CK-2018571, selectively inhibits ATP hydrolysis and relaxes smooth muscle in vitro, at the Biophysical Society 54th Annual Meeting; 2010 Feb 20-24; San Francisco, CA. Biophysical Society, Rockville, MD.
3. De Angelis K, Gama VM, Farah VA, and Irigoyen MC (2005) Blood flow measurements in rats using four color microspheres during blockade of different vasopressor systems. Braz J Med Biol Res 38:119-125. (Pubitemid 40277947)
4. Gavras H and Liang C (1980) Acute renovascular hypertension in conscious dogs. Interaction of the renin-angiotensin system and sympathetic nervous system in systemic hemodynamics and regional blood flow responses. Circ Res 47:356-365.
5. Gelpi RJ, Hittinger L, Fujii AM, Crocker VM, Mirsky I, and Vatner SF (1988) Sympathetic augmentation of cardiac function in developing hypertension in conscious dogs. Am J Physiol Heart Circ Physiol 255:H1525-H1534.
6. Gelpi RJ, Pasipoularides A, Lader AS, Patrick TA, Chase N, Hittinger L, Shannon RP, Bishop SP, and Vatner SF (1991) Changes in diastolic cardiac function in developing and stable perinephritic hypertension in conscious dogs. Circ Res 68:555-567.
7. Greenberg BH, Chou W, Saikali KG, Escandon R, Lee JH, Chen M, Malik F, Wolff AA and Shaburishvili T (2009) Phase II safety study evaluating the novel cardiac myosin activator, CK-1827452, in patients with ischemic cardiomyopathy and angina, at the Heart Failure Society of America Annual Meeting; 2009 Sept. 13-16; Boston, MA. Heart Failure Society of America, St. Paul, MN.
8. Gustafsson D (1987) Microvascular mechanisms involved in calcium antagonist edema formation. J Cardiovasc Pharmacol 10(Suppl 1):S121-S131.
9. Gustafsson D, Lanne T, Bjerkhoel P, Johansson P, and Lundvall J (1989) Microvascular effects and oedema formation of felodipine in man. J Hypertens Suppl 7:S161-S167; discussion S168.
10. Habibzadeh MR, Schiller NB, Malik FI, Chen MM, Saikali KG, Wolff AA, Goldman JH and Teerlink JR (2010) Effect of the selective cardiac myosin activator, omecamtiv mecarbil, on left atrial performance in healthy men, at the Heart Failure Society of America Annual Meeting; 2010 Sept 12-15; San Diego, CA. Heart Failure Society of America, St. Paul, MN.
11. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington DC.
12. Kirby DA and Vatner SF (1987) Enhanced responsiveness to carotid baroreceptor unloading in conscious dogs during development of perinephritic hypertension. Circ Res 61:678-686. (Pubitemid 17157308)
13. Knight DR, Kirby DA, and Vatner SF (1985) Effects of a calcium channel blocker on cardiac output distribution in conscious hypertensive dogs. Hypertension 7:380-385. (Pubitemid 15021177)
14. Leonetti G, Magnani B, Pessina AC, Rappelli A, Trimarco B, Zanchetti A, and COHORT Study Group (2002) Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens 15:932-940. (Pubitemid 35217397)
15. Levine TB, Olivari MT, and Cohn JN (1984) Hemodynamic and regional blood flow response to captopril in congestive heart failure. Am J Med 76:38-42. (Pubitemid 14106343)
16. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, et al. (2010) Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 121:e46-e215.
17. Malik FI, Hartman JJ, Elias KA, Morgan BP, Rodriguez H, Brejc K, Anderson RL, Sueoka SH, Lee KH, Finer JT, et al. (2011) Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science 331:1439-1443.
18. Mancia G and Ferrari AU (1992) Haemodynamic effects of a new multifactorial antihypertensive drug. Eur Heart J 13(Suppl A):26-29.
19. Messerli FH (2002) Vasodilatory edema: a common side effect of antihypertensive therapy. Curr Cardiol Rep 4:479-482.
20. Morano I, Chai GX, Baltas LG, Lamounier-Zepter V, Lutsch G, Kott M, Haase H, and Bader M (2000) Smooth-muscle contraction without smooth-muscle myosin. Nat Cell Biol 2:371-375.
21. Pedrinelli R, Dell'Omo G, Melillo E, and Mariani M (2000) Amlodipine, enalapril, and dependent leg edema in essential hypertension. Hypertension 35:621-625. (Pubitemid 30108158)
22. Qian X, Chuang C, Lu P, Yao B, Lu Q, Jiang H, Wang W, Morgan BP, and Morgans DJ (2009a) inventors; Cytokinetics Inc., assignee. Certain chemical entities, compositions, and methods. U.S. Patent Publication No. US 2009-0275537 A1; 2009 Nov 5.
23. Qian X, Wang X, Hartman J, Jia Z, Clancy S, Yao B, Chuang C, Lu P, Pannirselvam M, Morgans D, et al. (2009b) A direct inhibitor of smooth muscle myosin as a novel therapeutic approach for the treatment of systemic hypertension, at the American Society of Hypertension 24th Annual Scientific Meeting and Exposition; 2009 May 6-9; San Francisco, CA; American Society of Hypertension, New York.
24. Rendell MS, Shehan MA, Kahler K, Bailey KL, and Eckermann AJ (1997) Effect of calcium channel blockade on skin blood flow in diabetic hypertension: a comparison of isradipine and atenolol. Angiology 48:203-213. (Pubitemid 27118401)
25. Salmasi AM, Belcaro G, and Nicolaides AN (1991) Impaired venoarteriolar reflex as a possible cause for nifedipine-induced ankle oedema. Int J Cardiol 30:303-307.
26. Shen YT, Malik FI, Zhao X, Depre C, Dhar SK, Abarzúa P, Morgans DJ, and Vatner SF (2010) Improvement of cardiac function by a cardiac myosin activator in conscious dogs with systolic heart failure. Circ Heart Fail 3:522-527.
27. Shen YT and Vatner SF (1993) Effects of a K+ ATP channel opener, lemakalim, on systemic, coronary and regional vascular dynamics in conscious dogs: comparison with nifedipine, adenosine, nitroglycerin and acetylcholine. J Pharmacol Exp Ther 265:1026-1037.
28. Vatner DE, Kirby DA, Homcy CJ, and Vatner SF (1985) β-Adrenergic and cholinergic receptors in hypertension-induced hypertrophy. Hypertension 7:I55-I60.
29. Watanabe M, Yumoto M, Tanaka H, Wang HH, Katayama T, Yoshiyama S, Black J, Thatcher SE, and Kohama K (2010) Blebbistatin, a myosin II inhibitor, suppresses contraction and disrupts contractile filaments organization of skinned taenia cecum from guinea pig. Am J Physiol Cell Physiol 298:C1118-C1126.